PL418671A1 - Przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 i ich zastosowania, hybrydomy produkujące rzeczone przeciwciała, kompozycje i zestawy diagnostyczne - Google Patents

Przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 i ich zastosowania, hybrydomy produkujące rzeczone przeciwciała, kompozycje i zestawy diagnostyczne

Info

Publication number
PL418671A1
PL418671A1 PL418671A PL41867116A PL418671A1 PL 418671 A1 PL418671 A1 PL 418671A1 PL 418671 A PL418671 A PL 418671A PL 41867116 A PL41867116 A PL 41867116A PL 418671 A1 PL418671 A1 PL 418671A1
Authority
PL
Poland
Prior art keywords
viruses
serotype
compositions
hybridomas
applications
Prior art date
Application number
PL418671A
Other languages
English (en)
Other versions
PL238020B1 (pl
Inventor
Violetta Sączyńska
Violetta Cecuda-Adamczewska
Anna Porębska
Katarzyna Florys
Anna Bierczyńska-Krzysik
Piotr Baran
Agnieszka Romanik-Chruścielewska
Grażyna Płucienniczak
Andrzej Płucienniczak
Piotr Borowicz
Krzysztof Kucharczyk
Bogusław Szewczyk
Original Assignee
Instytut Biotechnologii i Antybiotyków
Kucharczyk Krzysztof Techniki Elektroforetyczne Spółka Z Ograniczoną Odpowiedzialnością
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biotechnologii i Antybiotyków, Kucharczyk Krzysztof Techniki Elektroforetyczne Spółka Z Ograniczoną Odpowiedzialnością, Uniwersytet Gdański filed Critical Instytut Biotechnologii i Antybiotyków
Priority to PL418671A priority Critical patent/PL238020B1/pl
Priority to EP17784704.3A priority patent/EP3510045B1/en
Priority to US16/332,782 priority patent/US10696737B2/en
Priority to PCT/PL2017/000084 priority patent/WO2018048317A1/en
Publication of PL418671A1 publication Critical patent/PL418671A1/pl
Publication of PL238020B1 publication Critical patent/PL238020B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Przedmiotem zgłoszenia są przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 wybrane z grupy obejmującej G-1-31-22, G-2-14-10, G-5-32-5, G-6-42-42, G-7-24-17 i G-7-27-18, mające szerokie zastosowanie w immunoprofilaktyce i immunoterapii zakażeń wywołanych przez wirus grypy, serotypu H5 u ludzi i zwierząt. Zgłoszenie obejmuje też hybrydomy produkujące przedmiotowe przeciwciała oraz kompozycje i zestawy diagnostyczne zawierające przedmiotowe przeciwciała do wykrywania i oznaczania wirusów grypy serotypu H5 oraz przeciwciał przeciwko wirusom grypy serotypu H5 w próbach biologicznych.
PL418671A 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne PL238020B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL418671A PL238020B1 (pl) 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne
EP17784704.3A EP3510045B1 (en) 2016-09-12 2017-09-11 Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits
US16/332,782 US10696737B2 (en) 2016-09-12 2017-09-11 Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits
PCT/PL2017/000084 WO2018048317A1 (en) 2016-09-12 2017-09-11 Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL418671A PL238020B1 (pl) 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne

Publications (2)

Publication Number Publication Date
PL418671A1 true PL418671A1 (pl) 2018-03-26
PL238020B1 PL238020B1 (pl) 2021-06-28

Family

ID=60117726

Family Applications (1)

Application Number Title Priority Date Filing Date
PL418671A PL238020B1 (pl) 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne

Country Status (4)

Country Link
US (1) US10696737B2 (pl)
EP (1) EP3510045B1 (pl)
PL (1) PL238020B1 (pl)
WO (1) WO2018048317A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018212924A1 (en) * 2017-01-30 2019-07-04 Cedars-Sinai Medical Center Diagnosis of scleroderma
CN111117970B (zh) * 2020-01-20 2020-11-17 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种识别n6亚型禽流感病毒神经氨酸酶蛋白的单克隆抗体及其应用
KR102517114B1 (ko) * 2020-08-28 2023-04-03 원광대학교산학협력단 고병원성 조류 인플루엔자 바이러스 h5 아형에 특이적인 단클론항체 및 이를 이용한 신속 진단 키트
CN112175072B (zh) * 2020-09-23 2022-06-28 浙江大学医学院附属第一医院 抗h5亚型禽流感病毒血凝素蛋白单克隆抗体zju5-01及其应用
KR102605065B1 (ko) * 2021-10-14 2023-11-22 원광대학교산학협력단 고병원성 조류 인플루엔자 바이러스 h5n1에 특이적인 단클론항체 및 이를 이용한 신속 진단 키트

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124092B2 (en) * 2007-03-13 2012-02-28 Institute For Research In Biomedicine Antibodies against H5N1 strains of influenza A virus
SG183032A1 (en) 2007-09-13 2012-08-30 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to hemagglutininand neuraminidase from influenza virus h5-subtypeor n1-subtype and uses thereof
WO2012054745A1 (en) * 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
US9233152B2 (en) * 2012-01-12 2016-01-12 Temasek Life Sciences Laboratory Limited Monoclonal antibodies targeting neutralizing epitopes on H5 influenza virus of clade 2.3

Also Published As

Publication number Publication date
WO2018048317A1 (en) 2018-03-15
EP3510045A1 (en) 2019-07-17
PL238020B1 (pl) 2021-06-28
US20190352375A1 (en) 2019-11-21
US10696737B2 (en) 2020-06-30
EP3510045B1 (en) 2021-11-03
WO2018048317A8 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
PL418671A1 (pl) Przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 i ich zastosowania, hybrydomy produkujące rzeczone przeciwciała, kompozycje i zestawy diagnostyczne
BR112019002687A2 (pt) receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
CL2018002797A1 (es) Receptores quiméricos y métodos de uso de los mismos.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
BR112018076260A2 (pt) anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
EA201992027A1 (ru) Водный состав антитела против pd-l1
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
EA201991876A1 (ru) Антитела против фактора d и их применения
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
CR20210094A (es) ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
ZA202104989B (en) Monoclonal antibodies specific for the pb2 antigen of the human influenza virus (flu), nucleotide sequences, method and diagnostic kit for flu infection
CL2021001441A1 (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932)
MX2024006293A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.